Electromed (ELMD) The 38th Annual Roth Conference summary

Company overview and financials

• Focuses on airway clearance in the respiratory care space, with a 35-year history and public since 2010.

• Generates about $70 million in revenue and $12 million in operating income, with no debt.

• Maintains profitability and strong cash generation, enabling share repurchases and organic investment.

• Completed $10 million in share repurchases last fiscal year, with another $10 million authorized.

Product innovation and differentiation

• SmartVest provides 360-degree therapeutic support, using a patented single-hose, lightweight, Velcro-closure vest.

• Designed for ease of use, especially for older, frail patients, with a simple touchscreen interface.

• Offers a lifetime warranty, reducing out-of-pocket expenses for patients.

• Differentiates from competitors with comfort, ergonomics, and high patient retention.

Market landscape and growth opportunities

• Addressable market includes 925,000 diagnosed bronchiectasis patients, but only 150,000 currently use HFCWO technology.

• Estimated $3 billion market opportunity, with significant untapped potential among undiagnosed COPD patients.

• Plans to expand sales force to 61 reps and target high-diagnosing, low-prescribing pulmonologists.

• Direct-to-consumer outreach and partnerships with respiratory therapists support market penetration.